Search Results
Your search for ,NOn matches 5550 pages
Showing 101 - 150FDA Approves Regimen for BRCA2-Mutated Metastatic Castration-Sensitive Prostate Cancer
On December 12, the U.S. Food and Drug Administration (FDA) approved the PARP inhibitor niraparib and the hormone therapy abiraterone acetate (Akeega) with prednisone for adults with deleterious or suspected deleterious BRCA2-mutated metastatic castration-sensitive prostate cancer, as determined by ...
CD40 Overexpression Emerges as a Potential Biomarker for Angioimmunoblastic T-Cell Lymphoma
Researchers at The University of Texas MD Anderson Cancer Center have identified CD40 overexpression as a potential prognostic biomarker in angioimmunoblastic T-cell lymphoma (AITL), a rare subtype of non-Hodgkin lymphoma that is difficult to diagnose and treat. The results of their study were...
P-RAD Trial Shows Increased T-Cell Infiltration With Preoperative Radiation Added to Anti–PD-1 Therapy in Early Breast Cancer
Preoperative radiation therapy added to anti–PD-1 immune checkpoint inhibition led to a significant increase in T-cell infiltration in patients with hormone receptor–positive/HER2-negative early-stage breast cancer, according to findings from the phase II P-RAD trial presented at the 2025 San...
AI Tops Density in Predicting Breast Cancer Risk
An image-only artificial intelligence (AI) model for predicting the 5-year risk of breast cancer provided stronger and more precise risk stratification than breast density assessment, according to a news statement issued about a study presented at the annual meeting of the Radiological Society of...
Ironically, Smoking May Have Saved My Life
I was diagnosed with stage IV non-small cell lung (NSCLC) adenocarcinoma on August 1, 2013—World Lung Cancer Day. If it hadn’t been for an article that caught my eye the year before about the recommendation from the United States Preventive Services Task Force that all men aged 65 to 75 who have...
Lifileucel Demonstrates Feasibility and Disease Stability in Advanced Head and Neck Squamous Cell Carcinoma
A single administration of autologous tumor-infiltrating lymphocyte (TIL) cell therapy with lifileucel led to disease stability in patients with recurrent and/or metastatic head and neck squamous cell carcinoma, even among patients whose disease had progressed or did not respond to multiple prior...
Christine M. Lovly, MD, PhD, FASCO, Named Head, Thoracic Oncology, at City of Hope
Christine M. Lovly, MD, PhD, FASCO, an expert on lung cancer with almost 2 decades of experience in clinical care, translational research, and academic leadership, will spearhead the new national thoracic oncology program at City of Hope in Duarte, California. In her new role, effective January 1, ...
ASCO Statement: HHS Revision of Black Box Warning for Hormone Replacement Therapy and its Implications for Cancer Care
On November 10, 2025, the Department of Health and Human Services announced that the Food and Drug Administration will begin to remove the “black box” warning language related to increased risks of cardiovascular disease, breast cancer, and probable dementia from hormone replacement therapy (HRT)...
High Risk of Metastatic Recurrence Among Young Patients With Cancer
A new study of adolescents and young adults (AYAs) with seven common cancers reveals that nearly one in ten patients diagnosed with non-metastatic disease later develop metastatic recurrence. The information was shared in a news statement from the UC Davis Comprehensive Cancer Center. Scientists at ...
Eliminating Barriers to Care for Patients With Intellectual and/or Developmental Disabilities
A recent large, retrospective study by Giblon et al has found that individuals with intellectual and/or developmental disabilities face an increased risk of developing cancer, higher symptom burden once they get cancer compared with those without such disabilities, and disparities in accessing...
Rainer Storb, MD, Receives Distinguished Wallace H. Coulter Award at ASH Annual Congress
The American Society of Hematology (ASH) presented the Wallace H. Coulter Award for Lifetime Achievement in Hematology to Rainer Storb, MD, during the Society’s Annual Congress held in Orlando. Dr. Storb is Professor Emeritus, Clinical Research Division, at Fred Hutch in Seattle. First awarded in...
One in Three Families of Children With ALL Face Financial Hardship During Treatment
A new multicenter study reports that nearly one-third of families with children undergoing chemotherapy for acute lymphoblastic leukemia (ALL) develop substantial financial hardships during the 2 years of treatment. These difficulties—defined as the inability to pay for housing, food, or utilities, ...
How AI Is Ushering in a New Era in Cancer Care
On October 30, 2025, Google Cloud held its second annual Cancer AI Symposium to explore how artificial intelligence (AI) is advancing cancer research, diagnosis, and treatment, in unparalleled ways. Held at Google’s St. John’s Terminal office in New York City, the event brought together leaders in...
Non–Total Body Irradiation Conditioning Regimen for Young Patients With MRD-Negative B-ALL
Two-year event-free survival rates were above 75% for children, adolescent, and young adult patients with B-cell acute lymphocytic leukemia (B-ALL) who had negative measurable residual disease (MRD) by next-generation sequencing prior to hematopoietic cell transplantation and who received a...
Research Supports FDA Approval of Sevabertinib for HER2-Mutant Lung Cancer
The U.S. Food and Drug Administration (FDA) has approved sevabertinib, an oral targeted therapy, for adult patients with non-small-cell lung cancer (NSCLC) whose tumors harbor certain HER2 (ERBB2) mutations and who have previously received chemotherapy or immunotherapy. The approval reflects a...
Cyclophosphamide-Based Strategy Enables Safe Transplant From Broadly Mismatched Donors
Clinicians have traditionally prioritized high-level human leukocyte antigen (HLA) matching to minimize graft-vs-host disease (GVHD) after hematopoietic cell transplantation (HCT). New data from the ACCESS study, sponsored by the National Marrow Donor Program, indicate that the use of...
New FDA-Approved Oncology Drugs and Label Updates Between December 1, 2024, and November 19, 2025
Over the past year (December 2024–November 19, 2025), the U.S. Food and Drug Administration (FDA) approved and expanded indications for many drugs related to the treatment of different types of cancers. The new approvals and accelerated approvals are listed below according to the most recent new...
Primary Analysis Shows Survival Benefit With Bemarituzumab Plus Chemotherapy in Gastric or Gastroesophageal Junction Cancer
The addition of bemarituzumab, a first-in-class anti-FGFR2b antibody, to mFOLFOX6 chemotherapy significantly improved overall survival in patients with FGFR2b-overexpressing (≥ 10% tumor cell staining) unresectable, locally advanced or metastatic gastric or gastroesophageal junction cancer,...
Sacituzumab Tirumotecan Improves Survival in EGFR-Mutated NSCLC After Tyrosine Kinase Inhibitor Failure
Sacituzumab tirumotecan, a novel TROP2 antibody-drug conjugate, was found to significantly improve both progression-free and overall survival compared with platinum-based chemotherapy in patients with EGFR-mutated non–small cell lung cancer (NSCLC) who had experienced disease progression following...
Final Analysis Supports Use of Durvalumab Plus BCG Infusions in High-Risk Non–Muscle-Invasive Bladder Cancer
In patients with high-risk non–muscle-invasive bladder cancer, the addition of 1 year of the PD-L1 inhibitor durvalumab to standard induction and maintenance bacillus Calmette-Guérin (BCG) infusions led to a statistically significant and clinically meaningful improvement in disease-free survival...
AACR Pediatric Cancer Progress Report Highlights Advances Made, Long-Term Survivorship Challenges, and Persistent Disparities in Care
Although treatment advances in pediatric cancers have resulted in increases in overall 5-year survival for children and adolescents diagnosed with cancer, many pediatric survivors face chronic health conditions as they age, as well as financial, social, and psychological challenges, according to...
Total Neoadjuvant Therapy and Nonoperative Management in pMMR/MSS Stage II to III Rectal Cancer
In an Italian phase II trial (NO-CUT) reported in The Lancet Oncology, Amatu et al found that total neoadjuvant therapy followed by nonoperative management in cases of complete response resulted in promising outcomes in patients with proficient mismatch repair or microsatellite stable (pMMR/MSS)...
Are Glycemic Index and Load Associated With Lung Cancer Risk?
Based on the results of a population-based cohort study published in Annals of Family Medicine by Wang et al, high dietary glycemic index is linked to increased risks of lung cancer, non–small cell lung cancer (NSCLC), and small cell lung cancer (SCLC), whereas glycemic load is inversely associated ...
Nivolumab and Ipilimumab in Advanced dMMR/MSI-H Noncolorectal Cancers
In an Australian and New Zealand phase II trial (MOST-CIRCUIT) reported in JAMA Oncology, Carlino et al found that combined anti–PD-1/CTLA-4 blockade was associated with a high rate of durable responses in patients with advanced mismatch repair–deficient/microsatellite instability–high (dMMR/MSI-H) ...
Retrospective Review Shows Persistent Breast Cancer Burden in Younger Women
Up to 24% of breast cancers diagnosed in an 11-year period between seven outpatient facilities around New York were found in women aged 18 to 49 years, according to findings presented during the 2025 Annual Meeting of the Radiological Society of North America (RSNA; Abstract S5-SSBR02-1). “This...
Exploratory FLAURA2 Analysis Confirms Overall Survival Benefit for Osimertinib in NSCLC Subgroups
An exploratory overall survival analysis of the phase III FLAURA2 trial confirmed the overall survival benefit of adding osimertinib to chemotherapy in patients with non–small cell lung cancer (NSCLC) and mutations in the epidermal growth factor receptor (EGFR) not previously treated for advanced...
External Validation Confirms Ability of AI Model to Stratify Recurrence Risk in Early-Stage Lung Cancer
A machine learning–based survival model, incorporating preoperative CT images and routinely available clinical data, outperformed standard clinical staging systems in predicting recurrence after surgery in patients with lung cancer, especially in stage I, and showed correlations with established...
As a Cancer Survivor, My Main Worry Now Is Affording Health Insurance
Until 3 years ago, cancer was so utterly frightening to me that I avoided discussing the disease or even mentioning the word as much as possible. I sympathized with a friend when she was diagnosed with lung cancer, but I never expected to be in her position. I’m a never-smoker, and except for a...
How an Endowed Chair in Cord Blood Research Is Providing New Hope for Patients With High-Risk Leukemia
In 2016, Filippo Milano, MD, PhD, Associate Professor, Translational Science and Therapeutics Division, and Director of the Cord Blood Transplant Program at Fred Hutchinson Cancer Center in Seattle, published the results of his landmark study investigating whether an alternative stem cell donor...
Significant Medicare Physician Reimbursement Methodology Changes Finalized for 2026
The Centers for Medicare & Medicaid Services (CMS) released the Medicare Physician Fee Schedule final rule for 2026 on October 31, 2025.1 The rule finalizes physician reimbursement and policy reforms under the Physician Fee Schedule as well as changes to reporting requirements and policy...
Zanzalintinib Plus Immune Checkpoint Inhibitor in Metastatic Colorectal Cancer
The phase III STELLAR-303 trial evaluated the anti-VEGFR–related multitargeted tyrosine kinase inhibitor zanzalintinib in combination with the PD-L1 inhibitor atezolizumab vs the multikinase inhibitor regorafenib in patients with previously treated non–microsatellite instability (MSI)–high...
Ivonescimab, a Dual-Targeting Bispecific Antibody, Improves Progression-Free Survival in Squamous NSCLC
In the phase III HARMONi-6 trial, conducted in China, the bispecific antibody ivonescimab, given with chemotherapy, improved progression-free survival by 4.2 months over the PD-1 inhibitor tislelizumab-jsgr plus chemotherapy, a 40% reduction in risk as first-line treatment of advanced squamous...
Proton vs Photon Radiation Therapy for Nonmetastatic Breast Cancer: Focus on Patient Perspective and Satisfaction
Health-related quality-of-life analyses for proton radiation therapy and photon radiation therapy in patients with nonmetastatic breast cancer showed similar impacts on quality of life with both treatments, according to findings from the phase III RadComp consortium trial. Shannon M. MacDonald, MD, ...
Long-Term Survival With Stereotactic Ablative Radiotherapy vs Surgery for Early-Stage NSCLC
With 10 years of follow-up, no significant difference in survival rates was reported between patients who were treated with stereotactic ablative radiotherapy (SABR) or video-assisted thoracoscopic surgery (VATS) for early-stage non–small cell lung cancer (NSCLC). These findings from the revised...
Treatment Advances in Malignant Hematology: 2025 Updates
The pace of therapeutic innovation in hematologic oncology continues to accelerate, moving clinical practice away from broad-spectrum chemotherapy and toward an era of highly personalized, biologically driven treatment. This transformation was the central theme of the 2025 National Comprehensive...
Primary Analysis Shows Survival Benefit With Bemarituzumab Plus Chemotherapy in Gastric or Gastroesophageal Junction Cancer
The addition of bemarituzumab, a first-in-class anti-FGFR2b antibody, to mFOLFOX6 chemotherapy significantly improved overall survival in patients with FGFR2b-overexpressing (≥ 10% tumor cell staining) unresectable, locally advanced or metastatic gastric or gastroesophageal junction cancer,...
Final Analysis Supports Use of Durvalumab Plus BCG Infusions in High-Risk Non–Muscle-Invasive Bladder Cancer
In patients with high-risk non–muscle-invasive bladder cancer, the addition of 1 year of the PD-L1 inhibitor durvalumab to standard induction and maintenance bacillus Calmette-Guérin (BCG) infusions led to a statistically significant and clinically meaningful improvement in disease-free survival...
Ivonescimab, a Dual-Targeting Bispecific Antibody, Improves Progression-Free Survival in Squamous NSCLC
In the phase III HARMONi-6 trial, conducted in China, the bispecific antibody ivonescimab, given with chemotherapy, improved progression-free survival by 4.2 months over the PD-1 inhibitor tislelizumab-jsgr plus chemotherapy, a 40% reduction in risk as first-line treatment of advanced squamous...
European Society for Medical Oncology Congress 2025 Meeting Highlights
The European Society for Medical Oncology (ESMO) Congress 2025 in Berlin featured many important trials with the potential to significantly influence clinical practice and improve outcomes for patients with multiple tumor types. These studies highlighted the benefits of novel treatment combination...
Pembrolizumab Plus Weekly Paclitaxel Improves Survival Outcomes in Platinum-Resistant Recurrent Ovarian Cancer
The addition of the PD-1 inhibitor pembrolizumab to weekly paclitaxel, with or without the VEGFA-targeted bevacizumab, significantly improved progression-free survival and overall survival in patients with platinum-resistant recurrent ovarian cancer, in the randomized, double-blind, phase III...
Addition of Durvalumab to BCG After TURBT for BCG-Naive, High-Risk NMIBC
In the final analysis of the phase III POTOMAC trial reported in The Lancet, De Santis et al found that the addition of durvalumab to bacillus Calmette-Guérin (BCG) induction and maintenance improved disease-free survival in patients with high-risk non–muscle-invasive bladder cancer (NMIBC) who...
Reducing the Barriers to Receiving CAR T-Cell Therapy for Patients With Hematologic Malignancies
Chimeric antigen receptor (CAR) T-cell therapy has transformed treatment for patients with hematologic malignancies, achieving unprecedented responses in some patients, especially those diagnosed with relapsed/refractory B-cell acute lymphocytic leukemia, non-Hodgkin lymphoma, and multiple...
FDA Grants Accelerated Approval to Sevabertinib for Nonsquamous NSCLC
On November 19, the U.S. Food and Drug Administration (FDA) granted accelerated approval to sevabertinib (Hyrnuo), a kinase inhibitor, for adults with locally advanced or metastatic nonsquamous non–small cell lung cancer (NSCLC) whose tumors have HER2 tyrosine kinase domain (TKD) activating...
Sacituzumab Tirumotecan Improves Survival in EGFR-Mutated NSCLC After Tyrosine Kinase Inhibitor Failure
Sacituzumab tirumotecan, a novel TROP2 antibody-drug conjugate, was found to significantly improve both progression-free and overall survival compared with platinum-based chemotherapy in patients with EGFR-mutated non–small cell lung cancer (NSCLC) who had experienced disease progression following...
Does Regular Opioid Use Increase Risks for Certain Cancers?
Regular pharmaceutical opioid use was found to be associated with an elevated risk for cancers previously associated with opium consumption, but not for other cancers, according to findings from a large-scale study led by the International Agency for Research on Cancer (IARC) that was published in...
HER3-DXd in Patients With Active Brain Metastases From NSCLC and Breast Cancer
In the phase II TUXEDO-3 trial—reported in two articles in The Lancet Oncology—Fuereder et al and Bartsch et al found that the topoisomerase-1 HER3-targeting antibody-drug conjugate patritumab deruxtecan (HER3-DXd) was active in cohorts of patients with active brain metastases from advanced...
Reducing the Impact of Climate-Induced Events on Patients and Oncology Staff
Although 2023 made headlines as the hottest year in human history,1 drawing the world closer to breaching the goals outlined in the Paris Agreement to substantially reduce global greenhouse gas emissions to limit global warming to well below 2°C above preindustrial levels (and preferably to...
A Serendipitous Fall May Have Saved My Life
In the spring of 2024, I was preparing to compete in a Half Ironman triathlon and was not surprised when I began experiencing tightness in my groin. I just figured it was the byproduct of specific endurance training I was doing in each discipline, including running, biking, and swimming, to get...
First-Line Ivonescimab or Tislelizumab Plus Chemotherapy in Advanced Squamous NSCLC
In an interim analysis of a Chinese phase III trial (HARMONi-6) reported in The Lancet, Chen et al found that the combination of ivonescimab—a bispecific antibody targeting PD-1 and VEGF—plus chemotherapy prolonged progression-free survival vs tislelizumab—an anti–PD-1 monoclonal antibody—plus...
Axicabtagene Ciloleucel in Relapsed or Refractory Indolent Non-Hodgkin Lymphoma: 5-Year Follow-up of ZUMA-5
As reported in the Journal of Clinical Oncology by Neelapu et al, the 5-year follow-up of the phase II ZUMA-5 trial has shown sustained responses with axicabtagene ciloleucel (axi-cel) in patients with relapsed or refractory indolent non-Hodgkin lymphoma. Study Details In the single-arm,...
